posted
One I am eyeing right now is XKEM looks like all but 2 trades so far have been buys and is currently trading at .024 check it out.
Posts: 487 | From: Northeast Ohio | Registered: Oct 2004
| IP: Logged |
posted
Have been in this one for a while. Have had a buy in at .015, hoping I could get more...does not look promising at that pps.
Posts: 3607 | From: NJ - Outside Phila. | Registered: Mar 2004
| IP: Logged |
NEW BRUNSWICK, N.J., Feb 17, 2005 (BUSINESS WIRE) -- Xechem International Inc. (XKEM) today announced significant progress in its development efforts for NICOSAN(TM)/ HEMOXIN(TM), a natural product extract which shows promise in the treatment of Sickle Cell Disease (SCD). Xechem has an exclusive world-wide license for the development and sale of NICOSAN(TM)/ HEMOXIN(TM) from the National Institute for Pharmaceutical Research and Development (NIPRD), Abuja, government of Nigeria, which holds the patent.
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
posted
Starting to run now and volume is picking up. .028 x .029 volume about 1,600,000. Jonathan
Posts: 64 | From: Leominster, MA | Registered: Dec 2004
| IP: Logged |
posted
it wasn't exactly stellar news, but it eased my concerns about inactivity. i am looking forward to the upcoming months. this was a steal, thanks to the ridiculously stupid nature of reverse splits.
Posts: 393 | Registered: Jul 2003
| IP: Logged |
posted
great news - only the stock in portfolio is worth $19m !!!
-- Xechem International Inc. (XKEM) today announced that its corporate spinoff, Ceptor Corporation, has successfully completed a $12,000,000 private offering and is now an independent company whose shares are traded on the NASD over the counter bulletin board, under the symbol CEPO. Ceptor is engaged in the development of technology for the treatment of neuromuscular and neurodegenerative diseases such as muscular dystrophy, multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). As a result of the transaction, Xechem continues to hold 3,386,563 shares of Ceptor or approximately 14% on a fully diluted basis, assuming full conversion of all shares sold in the private placement and other exercises and conversions. In addition, pursuant to Xechem's spin off agreement with Ceptor, Xechem has been paid $1,279,125 by Ceptor and is entitled to receive an additional $720,875 from future Ceptor financings in redemption of Ceptor stock held by Xechem, following which, the redemption pursuant to the spin off agreement will be complete. The proceeds of Xechem's sale of Ceptor's stock, pursuant to the redemption provision of the spin off agreement, are being used for Xechem's internal working capital purposes. Ceptor stock closed at $5.80 per share on Tuesday, February 22, 2005.
Posts: 1442 | From: Lugano - Switzerland | Registered: Sep 2003
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
